Prostate cancer study aims to restore testosterone after Long-Term therapy

NCT ID NCT06463457

Ongoing Disease control Sponsor: Atish Choudhury, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether testosterone levels can return to normal after two years of treatment with relugolix and darolutamide in men with hormone-sensitive prostate cancer. About 33 participants will receive the drug combination and be monitored for testosterone recovery and side effects. The goal is to see if a limited treatment course can control the disease while allowing the body to recover hormone function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PROSTATE CANCER HORMONE SENSITIVE PROSTATE CANCER PROSTATE CANCER

Contacts and locations

Show contact details

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Brigham and Women's Hospital

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States